EGFR Inhibitor Skin Toxicity Tool (MESTT)

©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide.


About the MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT)

The MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT) © was developed by the MASCC Skin Toxicity Study Group in 2008 as a tool to assist oncology health professions with the monitoring and reporting of dermatologic adverse events in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.

MASCC is grateful to the following individuals and organizations for their help in developing the MAT: 

Project Participants

Robert Baran, MD
Andrei Barasch, DMD
Ethan Basch, MD
Alice Chen, MD
Janet E. Dancey, MD
Beth Eaby, CRNP
Lawrence Einhorn, MD
Joel B. Epstein, DMD
Lindy P Fox, MD
Judi Johnson, RN, PhD
Mark Kris, MD
Sandra Kurtin, RN
Mario E Lacouture*, MD
Michael L. Maitland, MD
Bernardo L. Rapoport, MD
Cynthia Rittenberg, RN
Elise Olsen, MD
Siegfred Segaert, MD
Andy Trotti, MD
Lynne Wagner, PhD
Dennis P West, MD

*Dr. Mario E. Lacouture (Organizing and Overall Meeting Chair) is supported by a Zell Scholarship from the Robert H Lurie Comprehensive Cancer Center.

 

This project was supported by OSI Pharmaceuticals and Amgen, Inc.


The MASCC EGFR Inhibitor Skin Toxicity Tool & Associated Resources

The MESTT
altCaring for your skin, hair and nails on "Targeted Therapies" (Patient Brochure)
altClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Supportive Care in Cancer, Volume 19, Number 8, 1079-1095, DOI: 10.1007/s00520-011-1197-6. Mario E. Lacouture, Milan J. Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B. Epstein, Beth Eaby-Sandy, Barbara A. Murphy and MASCC Skin Toxicity Study Group.


MESTT© Approval

Non-profit entities and health professionals (physicians, nurses, etc.) are encouraged to use the MESTT and may do so free of charge. Commercial companies will require written approval from MASCC, and will incur a nominal fee prior to using this tool. Please contact the Executive Director at [email protected] for additional information regarding the approval procedure.

 

MESTT ©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide.
For questions or additional information, contact the Executive Director at [email protected].